GSK3B and Alzheimer disease: Chronic treatments of AD mice with an IL-1 receptor (IL-1R) or TNF-α blocking antibodies significantly reduce the activity of Glycogen synthase kinase-3β (GSK3β), brain inflammatory responses, cognitive deficits, tau pathology, and both fibrillar and oligomeric forms of Aβ [17,18,19].